safety and efficacy of chemotherapy combined with radiotherapy for maxillary sinus carcinomas

safety and efficacy of chemotherapy combined with radiotherapy for maxillary sinus carcinomas - chemotherapy combined with radiotherapy for maxillary sinus carcinomas

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002131

Enrollment

Registered

2009-06-29

Start date

2009-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

maxxillary sinus carcinoma

Interventions

systemic chemoterapy(two cycles,first and fifth week, 5 days ,5FU 800mg/mm3) superselective intraarterial infusion chemotherapy(three cycles CDDP) radiation therapy(50Gy)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) maxillary sinus carcinoma 2) enhanced CT 3) squamous cell carcinoma 4) performance status:0 or 1 5) WBC 3000/mm3 or more Platelets 80000/mm3 or more 6) creatinine clearance 60ml/minute or more

Exclusion criteria

Exclusion criteria: 1) distant metastasis 2) stenosis or sclerosis of carotid artery 3) 75 years old over

Design outcomes

Primary

Measure	Time frame
safety	—

Secondary

Measure	Time frame
efficacy	—

Countries

Japan

Contacts

Public ContactKazuya Otsu

Mie University Graduate School of Medicine Department of Otorhinolaryngology-head and neck surgery

otsu3mk@nifty.com059-232-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026